AkesoFRA:4RY -4.29%54 Gross Margin % is 78.02% as of Dec. 2025, which is 10% below its 10-year median of 86.39. GuruFocus rates FRA:4RY with a GF Score™ of 54/100 and a GF Value™ of €15.78 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 736 Biotechnology companies, Akeso ranks better than 70.65% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Akeso's Gross Profit for the
six
months ended in Dec. 2025 was €155.6 Mil. Akeso's Revenue for the
six
months ended in Dec. 2025 was €199.4 Mil. Therefore, Akeso's Gross Margin % for the quarter that ended in Dec. 2025 was 78.02%.
The historical rank and industry rank for Akeso's Gross Margin % or its related term are showing as below:
FRA:4RY'
s Gross Margin % Range Over the Past 10 Years
Min: 78.65 Med: 86.39 Max: 97.06
Current: 78.65
During the past 8 years, the highestGross Margin % of Akeso was 97.06%. The lowest was 78.65%. And the median was 86.39%.
FRA:4RY's Gross Margin % is ranked better than 70.65% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs FRA:4RY: 78.65
Akeso had a gross margin of 78.02% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Akeso was 0.00% per year.
Akeso (FRA:4RY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Akeso had a gross margin of 78.02% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Akeso Gross Margin % Related Terms
Akeso Gross Margin % Historical Data
* Premium members only.
The historical data trend for Akeso's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RY vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Akeso's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Akeso's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Akeso (FRA:4RY) has a Gross Margin % of 78.02% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Akeso and its competitors. This is 10% below median its historical median of 86.39. Over the past decade, Akeso's Gross Margin % has ranged from 78.65 to 97.06. According to the industry distribution chart, Akeso ranks #216 out of 736 companies in the Biotechnology industry, placing it in the top 29.3%.
Is Akeso's Gross Margin % too high?
Akeso's current Gross Margin % of 78.02% is 10% below median its 10-year median of 86.39. Over the past 10 years, this metric has ranged from a low of 78.65 to a high of 97.06. The Biotechnology industry median Gross Margin % is 60.91. Akeso's value of 78.02% is 28.1% above this industry median. Based on the distribution chart, Akeso ranks #216 out of 736 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Akeso has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Akeso's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Akeso ranks #216 out of 736 companies for Gross Margin %. This puts Akeso in the upper half of its industry. The industry median Gross Margin % is 60.91. Akeso's value of 78.02% is 28.1% above this benchmark. Historically, Akeso's own Gross Margin % has ranged from 78.65 to 97.06 over the past decade. While the company's 10-year median is 86.39 vs. the industry median of 60.91, Akeso has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akeso's current Gross Margin % of 78.02% is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Akeso and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akeso's current Gross Margin % is 78.02%, which is 10% below median its own 10-year median of 86.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Possible Value Trap. The stock's GF Value™ is €15.78, compared to a current price of €9.19 — trading 41.8% below its estimated fair value. The current Gross Margin % is 78.02%, which is 10% below median its 10-year median of 86.39 and 28.1% above the Biotechnology industry median of 60.91. Akeso's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Akeso (FRA:4RY), the current Gross Margin % is 78.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akeso (FRA:4RY) Overvalued in 2026?
Based on GuruFocus' analysis, Akeso stock appears to be undervalued.
The current stock price of €9.19 is trading 41.8% below its estimated GF Value™ of €15.78.
GuruFocus considers Akeso to be Possible Value Trap.
Key valuation signals for FRA:4RY:
Gross Margin %: 78.02% (10% below median its 10-year median of 86.39)
GF Value™: €15.78 vs. price of €9.19 (41.8% below fair value)
Industry Position: 28.1% above the Biotechnology median (#216 of 736)
No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
54GF Score
Get the complete analysis for FRA:4RY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RY has been successfully added to your 
